Business Wire

SEOUL-SEMICONDUCTOR

20.10.2020 04:32:07 CEST | Business Wire | Press release

Share
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected for European Kindergarten Lighting to Support Children’s Learning and Eye Health

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that LED Luks , a European manufacturer of LED luminaires, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for private kindergarten facilities’ lighting in Slovenia to support children’s learning and eye health.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005912/en/

In cooperation with LED Luks, Seoul Semiconductor has developed the optimal SunLike Series LED designs based on the natural spectrum light source for the lighting. With SunLike Series natural spectrum LED technology, LED Luks has used lighting brand “ARUN” to support children’s concentration and relaxation with an optimal smart solution for remotely and automatically adjusting the color temperature and dimming representing the light from noon to evening.

The light in noon color mode helps children’s brains more alert and also improve academic performance. The light in the evening color mode makes them more creative and feel relaxed. It also provides high sleep quality by promoting melatonin, thus encouraging the production of growth hormone and boosting memory and immunity. Human body produces growth hormone up to 80% of the daily GH production during sleep. Deep, non-REM sleep helps human brain to wash away waste and to regenerate cells, supporting immunity.

Earth is estimated to be 4.5 billion years old. With natural sunlight, under which all animals on the earth have evolved over 3.9 billion years, plants over 450 million years, insects over 360 million years, and humans over 7 million years. Based on circle of day – month – year, human’s DNA has evolved and a circadian rhythm is internal process that regulates the sleep-wake cycle based on 24-hour body clock that natural sunlight affects.

SunLike Series LEDs are the world’s first technology and have been recognized as an innovative technology that produces light that closely matches the spectrum of natural sunlight by a total of ten global lighting awards held in Korea, Europe, China, and the US over the past three years. Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, LED light sources with the same measured intensity and correlated color temperature (CCT), but different spectral output, can have different effects on human behavior and physiology. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.” According to the results of a study done by the Bio-Information Laboratory of Seoul National University Hospital in July of 2018, SunLike Series natural spectrum LEDs have been shown to reduce eye discomfort and improve sleep patterns. In addition, Seoul Semiconductor has been conducting experiments on protection from myopia and students’ learning and concentration with influential university research teams in Europe and the US for three years, and is expected to announce the study results in the second half of 2020.

“Young people who spend long hours of indoor study and the lack of exposure to daylight particularly need to use a better quality of LED lighting which closely matches natural spectrum of sunlight,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “We believe that Seoul Semiconductor’s SunLike Series natural spectrum LEDs will be necessary technology for human-centric lighting to support human health, well-being and better performance of daily life, children’s healthy growth as well with three beneficial effects in contrast to conventional LEDs: Better Study, Better Eye Health and Better Immunity.”

Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sunlight spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phone, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye